INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXELGlobeNewsWire • 08/09/25
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?Zacks Investment Research • 08/05/25
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the StockZacks Investment Research • 08/04/25
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research • 07/30/25
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong BuyZacks Investment Research • 07/29/25
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 PlansBenzinga • 07/29/25
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire • 07/28/25
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 07/24/25
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 EarningsZacks Investment Research • 07/23/25
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/21/25
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025Business Wire • 07/14/25